GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the third quarter ended 30th September 2012. The growth in Net Sales was 10% and Profit After Tax and before Exceptional Items was 12%. The core Pharmaceuticals business grew by 11% during the quarter.During the quarter, the Company launched Zimivir for herpes treatment. The Company expanded its CNS portfolio by launching Ictacetam used in the treatment of epilepsy. Commenting on the performance Dr. Hasit Joshipura, Managing Director, said “The vaccines business continues to record strong growth. The quarter also saw good growth across verticals, in particular, Specialities. Sales were impacted due to constraints of sterile manufacture owing to shutdown of one of the suppliers, as well as, on account of constraints at the Nashik facility. These constraints have since been resolved”.
By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…
By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital …
Kurnool, November 20, 2024: Adoni, Andhra Pradesh, – The Khazi India Foundation is pleased to…
New Delhi, November 20, 2024: Aakash Healthcare marked this year’s Children’s Day with a joyful…
Dr Agarwals Eye Hospital, Bengaluru, is providing free consultations for diabetic patients aged 50 and…
By Ms. Archana S, Senior Nutritionist, Aster Whitefield Hospital, Bengaluru As an essential nutrient, protein…